(702) 683-8946

Monday - Friday 9am to 5pm



Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)



CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform




Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business


Latest News Releases From The Newsroom

REV Group Beats Estimates; Bullish View On Immunocore

September 13th, 2023

REV Group, Inc. (NYSE: REVG) exceeded expectations in its third-quarter fiscal 2023 earnings report, posting adjusted earnings of $0.35 per share compared to the consensus EPS estimate of $0.23. The company also outperformed in terms of quarterly sal. Read more

Spirit Airlines Lowers Outlook; Alnylam Stock Halted Amid FDA Panel Review

September 13th, 2023

Shares of Spirit Airlines, Inc. (NYSE: SAVE) experienced a dip in pre-market trading as it revised downwardly its third-quarter 2023 outlook. The company now anticipates revenues between $1.245 billion and $1.255 billion, a notable decrease from its . Read more

Momentum Builds: Workhorse's IRS Determination; Edgio's Upbeat Q2 Results

September 13th, 2023

Shares of Workhorse Group Inc. (Nasdaq: WKHS) soared over 20% in after-hours trading following the company's announcement of IRS approval as a qualified manufacturer for the Commercial Clean Vehicle Credit. This approval opens the door for Workhorse . Read more

InnovAge Posts Mixed Results; Lockheed Martin Bags $841.4M+ Contract Modification

September 12th, 2023

InnovAge Holding Corp. (Nasdaq: INNV), a healthcare company, posted a fourth-quarter fiscal 2023 loss of $(0.09) per share, falling short of the consensus estimate loss of $(0.03). Nevertheless, the company reported quarterly sales of $176.87 million. Read more

Breaking: Asset Sale Deal Ignites Avalo Therapeutics

September 12th, 2023

Shares of Avalo Therapeutics, Inc. (Nasdaq: AVTX) surged by more than 40% following the company's announcement of a purchase agreement with AUG Therapeutics, LLC (AUG), wherein it will sell its rights, assets, and interests related to the 800 Series . Read more

Sight Sciences Takes a Hit: Revenue Outlook Falls Short

September 11th, 2023

Shares of Sight Sciences, Inc. (Nasdaq: SGHT) took a sharp nosedive in after-hours trading, plummeting over 15%. This drastic drop followed the company's announcement that its third-quarter 2023 total revenue is expected to be in the range of $19.0 m. Read more

Earnings Reaction Rollercoaster: Oracle Tumbles, Casey's Surges

September 11th, 2023

Oracle Corporation (NYSE: ORCL), a global technology company, reported first-quarter fiscal 2024 earnings of $1.19 per share, surpassing the consensus EPS estimate of $1.15. However, the company's quarterly revenues of $12.45 billion fell slightly be. Read more

FTC Says TruthFinder, Instant Checkmate Deceived Users About Background Report Accuracy, Violated FCRA While Marketing Reports for Employee and Tenant Screening

September 11th, 2023

Under proposed order, companies will pay $5.8 million penalty, implement FCRA monitoring program Washington D.C. / CRWE PRESS RELEASE / September 11, 2023 -  The Federal Trade Commission will require background report providers TruthFind. Read more

FuelCell Energy Posts Mixed Results; Bullish View On Kenvue

September 11th, 2023

FuelCell Energy, Inc. (Nasdaq: FCEL), a renewable energy company, reported a third-quarter fiscal 2023 loss of $(0.06) per share, better than the consensus estimate loss of $(0.08). The company's quarterly sales amounted to $25.51 million, slightly b. Read more

Momentum: Crinetics' Acromegaly Study Data and Tesla's Morgan Stanley Boost

September 11th, 2023

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) has reported promising results from its Phase 3 PATHFNDR-1 study evaluating paltusotine, an oral once-daily investigational compound designed for acromegaly treatment. The study achieved its primary endp. Read more